Copyright
©The Author(s) 2020.
World J Gastroenterol. Jul 21, 2020; 26(27): 3975-3988
Published online Jul 21, 2020. doi: 10.3748/wjg.v26.i27.3975
Published online Jul 21, 2020. doi: 10.3748/wjg.v26.i27.3975
Table 1 Summary of patient demographics and baseline disease characteristics, n (%)
| Variable | TACE/HAIC + S-1, n = 55 | TACE/HAIC, n = 60 | P value |
| Age in yr | 0.210 | ||
| mean ± SD (range) | 56.3 ± 10.9 (34-81) | 59.1 ± 12.7 (22-82) | |
| Sex | 0.709 | ||
| Male | 49 (89.1) | 51 (85.0) | |
| Female | 6 (10.9) | 9 (15.0) | |
| Liver disease etiology | 0.237 | ||
| HBV | 47 (85.5) | 45 (75.0) | |
| HCV | 4 (7.3) | 6 (10.0) | |
| HBV and HCV | 1 (1.8) | 0 | |
| Unknown | 3 (5.5) | 9 (15.0) | |
| Performance status | 0.756 | ||
| 0 | 40 (72.7) | 41 (68.3) | |
| 1 | 15 (27.3) | 19 (31.7) | |
| Child-Pugh stage | 0.642 | ||
| A | 47 (85.5) | 55 (91.7) | |
| B | 8 (14.5) | 5 (8.3) | |
| Tumor maximal size in cm | 0.530 | ||
| mean ± SD (range) | 9.7 ± 4.7 (2.2-25.3) | 10.2 ± 4.2 (2.5-21.0) | |
| Number of tumors | 0.683 | ||
| 1 | 16 (29.1) | 19 (31.7) | |
| ≥ 2 | 34 (61.8) | 38 (63.3) | |
| Infiltrative | 5 (9.1) | 3 (5.0) | |
| Portal vein invasion | 0.649 | ||
| No invasion | 21 (38.2) | 18 (30.0) | |
| Stage I-II | 24 (43.6) | 30 (50.0) | |
| Stage III-IV | 10 (18.2) | 12 (20.0) | |
| Extrahepatic metastasis | 0.274 | ||
| Yes | 41 (74.5) | 38 (63.3) | |
| No | 14 (25.5) | 22 (36.7) | |
| Targeted treatment | 0.846 | ||
| Yes | 9 (16.4) | 8 (13.3) | |
| No | 46 (83.6) | 52 (86.7) | |
| AFP in ng/mL | 0.579 | ||
| Median (range) | 4833 (0.9-1974770) | 5561 (0.6-1207090) |
- Citation: Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988
- URL: https://www.wjgnet.com/1007-9327/full/v26/i27/3975.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i27.3975